Control of Gene Expression in Eukaryotes

Every cell carries essentially the same DNA, yet a beta cell and a neuron behave nothing alike — the difference is which genes are expressed, when, and how much. Eukaryotic gene regulation is layered, operating at every level from chromatin architecture down to the fate of individual mRNAs. The MCAT tests how and why each control point works, and what goes wrong when it fails.

Priority labels: Must know = cold; Know the logic = mechanism not names; Passage-level = recognize, don't memorize; Optional = skippable.

---

Transcriptional Regulation

The Logic of Transcriptional Control

Must know

Transcription is the most economical control point — if you never make the mRNA, you spend nothing on splicing, translation, or folding. Turning a gene on or off involves assembling proteins at specific DNA sequences near (and sometimes far from) the gene.

Contrast with prokaryotes. Eukaryotes generally lack operons: each gene has its own promoter and gives a monocistronic mRNA (one mRNA → one protein), rather than co-regulating a cluster on one polycistronic transcript (as the bacterial lac/trp operons do). Coordinated expression is instead achieved by shared response elements bound by common transcription factors, with regulation spread across many layers.

Promoters, Enhancers, and Silencers

Must know

Every gene has a promoter, the DNA region just upstream of the transcription start site (+1) where the machinery assembles. The core promoter typically contains the TATA box (~25–30 bp upstream), which helps position RNA polymerase II. Optional — some promoters lack a TATA box and use other core elements instead, but the TATA box is the canonical MCAT model.

Beyond the core promoter, distant enhancers dramatically increase transcription. Enhancers are cis-acting DNA sequences (same chromosome) but can act over tens of thousands of base pairs, in either orientation, even downstream of the gene. The model: activator proteins bound at an enhancer contact promoter proteins through DNA looping, bringing the two regions together.

Silencers are analogous elements that decrease transcription when bound by repressors. Enhancers and silencers are cis-regulatory elements; the proteins that bind them are trans-acting factors (encoded elsewhere, diffuse to their targets). MCAT vocabulary: cis elements are DNA sequences; trans factors are proteins.

The Basal Transcription Machinery

Know the logic

RNA polymerase II cannot bind the promoter alone. It needs general (basal) transcription factors that assemble at the core promoter to form the initiation complex, positioning the polymerase at the start site. (Don't memorize individual general factors.)

This basal machinery gives only minimal, "leaky" transcription. Strong, regulated transcription requires gene-specific activators that bind enhancers and recruit coactivators, which bridge activators to the polymerase machinery.

Quick check: A mutation destroys the TATA box of a gene. What is the likely consequence for transcription of that gene?

Transcription will be severely reduced or absent because the basal machinery cannot be positioned at the core promoter. Basal transcription is lost even if enhancers and activators are intact, because the core promoter cannot assemble the initiation complex.

---

DNA Binding Proteins and Transcription Factors

Structure of a Transcription Factor

Must know

A transcription factor (TF) binds DNA sequence-specifically to regulate transcription. Most TFs are modular, with two independent functional domains:

1. A DNA-binding domain — recognizes a specific sequence (the response element), telling the factor where to bind
2. An activation (or repressor) domain — interacts with coactivators/chromatin remodelers, telling it what to do there

Common DNA-Binding Motifs

Must know

Recognize these motifs by name; you don't need their chemistry:

• Zinc finger — loop stabilized by a coordinated zinc ion.
• Leucine zipper — two α-helices dimerizing through hydrophobic leucines.
• Helix-turn-helix — two α-helices joined by a turn, one contacting DNA.

Many TFs act as dimers, and the dimer combination affects which sequences are bound and whether the gene is activated or repressed (one route to combinatorial control).

Response Elements and Hormonal Signaling

Know the logic

Nuclear hormone receptors (steroids, thyroid hormone, vitamin D, retinoic acid) are intracellular transcription factors. Because the ligands are lipid-soluble, they cross the membrane and bind the receptor inside the cell; the hormone–receptor complex then binds a response element in target genes and switches transcription on. This direct ligand-to-transcription route contrasts with cell-surface receptor signaling cascades.

Quick check: A researcher mutates the activation domain of a transcription factor but leaves the DNA-binding domain intact. What effect do you predict on target gene expression?

The mutant TF still binds its response element but cannot recruit coactivators or the basal machinery. It may even repress transcription by occupying the site and blocking endogenous activators (dominant-negative). Target gene expression decreases.

---

Gene Amplification and Duplication

Why Duplicate Genes?

Must know

Gene duplication is a major evolutionary mechanism: one copy keeps the original function while the other is free to mutate and evolve a new one. This generates gene families — related genes from a common ancestor (e.g., the globin genes).

Gene Amplification

Must know

Gene amplification is a selective increase in copy number of a specific gene (distinct from duplication). More copies → more product, so it raises expression. It occurs normally for genes needed in bulk, but also pathologically — cancer cells can amplify a proto-oncogene to drive overexpression and proliferation.

Quick check: A cancer cell treated with a chemotherapy drug becomes resistant after several weeks. Molecular analysis shows extra copies of the gene encoding the drug's target enzyme. What mechanism explains this resistance?

Gene amplification. The tumor cell has amplified the target gene, producing far more enzyme than the drug dose can inhibit — a classic amplification-driven resistance mechanism.

---

Post-Transcriptional Control

The Journey of a Pre-mRNA

Must know

Transcription produces a pre-mRNA (primary transcript), which is processed before export to the cytoplasm. This processing is a regulated control point, not just cleanup.

The 5' Cap and 3' Poly-A Tail

Must know

The 5' end gets a 7-methylguanosine cap ($\ce{m^7G}$): it protects against 5' exonucleases, aids nuclear export, and is recognized by translation initiation factors to recruit the ribosome.

The 3' end is cleaved and gets a poly-A tail (~200 adenosines added by poly-A polymerase): it protects against 3' exonucleases and promotes translation. Removing the tail (deadenylation) is often the first step in mRNA degradation, so tail length helps set mRNA stability and expression level.

Splicing: Introns and Exons

Must know

Eukaryotic genes contain introns — intervening sequences that must be precisely removed from the pre-mRNA. The retained, translated sequences are exons (expressed sequences).

Splicing occurs in the nucleus via the spliceosome, a complex of snRNPs that recognizes intron boundaries, excises the intron, and joins the flanking exons. (Detailed snRNP assembly is out of scope.)

Alternative Splicing

Must know

A single gene can yield multiple proteins through alternative splicing — including/excluding different exons by cell type or condition. This is a major reason the proteome exceeds the ~20,000-gene genome. Passage-level — if a passage shows one gene making tissue-specific isoforms, the mechanism is alternative splicing.

mRNA Stability and Translational Control

Know the logic

mRNA half-life affects protein output: a more stable transcript (tied to poly-A tail length and 3' UTR sequences) yields more protein, while targeted degradation shuts expression down. Expression is also tuned at translation initiation — cells can globally slow translation under stress or selectively repress/activate individual mRNAs. These controls adjust protein output without changing transcription.

Quick check: A mutation changes the conserved sequence at the 5' splice site of an intron so the spliceosome can no longer recognize it. What happens to splicing and the resulting protein?

The intron is not removed correctly and is typically retained in the mRNA. The retained intron usually disrupts the reading frame or introduces a premature stop codon, producing a nonfunctional or truncated protein.

---

Cancer as a Failure of Normal Cellular Controls

The Two Classes of Cancer Genes

Must know

Cancer arises when controls on proliferation and survival break down. Two gene categories drive malignancy:

Proto-oncogenes normally promote growth, proliferation, or survival. When mutated or overexpressed they become oncogenes driving uncontrolled growth — a gain-of-function change. One mutant allele is enough, so oncogenes act dominantly at the cellular level. Ras (a signaling protein that becomes constitutively active when mutated) is the classic example.

Tumor suppressor genes normally restrain division or trigger apoptosis after problems like DNA damage. Cancer needs both copies lost — a loss-of-function change — so tumor suppressors are recessive at the cellular level, requiring multiple "hits." The canonical examples are p53 ("guardian of the genome," arrests the cycle or triggers apoptosis after DNA damage) and Rb (blocks the G1→S transition). When lost, damaged cells divide instead of arresting or dying.

Quick check: A patient inherits one defective copy of a tumor suppressor gene. Does this mean they currently have uncontrolled cell growth? Why or why not?

Not necessarily. The one remaining normal copy is usually sufficient — tumor suppressors are recessive at the cellular level (multiple-hit model). Risk is elevated because only one more somatic "second hit" is needed to knock out the gene in a cell, but cells with one working copy behave normally.

---

Regulation of Chromatin Structure

Nucleosomes: The Basic Unit of Packaging

Must know

Eukaryotic DNA is wrapped around protein spools called nucleosomes: DNA around a histone octamer (two each of H2A, H2B, H3, H4). The linker histone H1 binds DNA between nucleosomes and packs them into higher-order structures ("beads on a string").

Key insight: tightly packaged DNA is inaccessible to the transcription machinery, so regulating chromatin compaction regulates gene expression.

Euchromatin vs. Heterochromatin

Must know

Euchromatin is loose, gene-rich, and transcriptionally active. Heterochromatin is compact and generally silent, in two types:

• Constitutive: permanently silenced (centromeres, telomeres).
• Facultative: can switch active/silent by cell type or stage — the inactive X (Barr body) is the canonical example.

Histone Modifications

Must know

Histone tails protrude from the nucleosome and carry post-translational modifications (the "histone code").

Histone acetylation. Histone acetyltransferases (HATs) add acetyl groups to lysines, neutralizing their positive charge and weakening the histone–DNA interaction. This loosens chromatin → activation. Histone deacetylases (HDACs) remove acetyls, restore the charge, tighten chromatin → repression.

Histone methylation is context-dependent — it can activate or silence depending on the site.

Chromatin Remodeling Complexes

Know the logic

ATP-dependent chromatin remodeling complexes physically reposition nucleosomes to expose specific DNA. Activators often recruit both HATs and remodelers to open a promoter before the machinery arrives.

Quick check: A drug inhibits HDACs in a cancer cell that has silenced a tumor suppressor gene via histone deacetylation. What is the predicted effect on chromatin structure and gene expression?

HDAC inhibition prevents removal of acetyl groups from histone tails. Histone tails remain acetylated, chromatin stays in the loose, accessible (euchromatin-like) conformation, and the silenced gene can be re-expressed. This is the rationale for HDAC inhibitors in cancer therapy.

---

DNA Methylation

Mechanism and Distribution

Must know

DNA methylation adds a methyl group to cytosine at CpG dinucleotides. Dense CpG islands in promoters are usually unmethylated in active genes; when methylated, the gene is silenced. Methylation is a heritable epigenetic mark — copied onto the new strand after replication — so silencing passes through cell divisions. It also recruits factors that compact chromatin, linking it to histone modification.

Genomic Imprinting and X-Inactivation

Must know

Two consequences of heritable epigenetic marks:

• Genomic imprinting = parent-of-origin expression: for some genes only the maternal or only the paternal copy is expressed, because the other was epigenetically silenced in the germline.
• X-inactivation silences one X in each female cell to equalize X-linked dosage with males. The inactive X condenses into a Barr body (facultative heterochromatin). The choice is random and clonally maintained, so females are mosaics for X-linked genes — why a heterozygous carrier can show patchy expression.

Quick check: A female inherits a mutant allele on one X chromosome and a normal allele on the other. Why might different patches of her tissue show different phenotypes?

Because X-inactivation is random and then clonally maintained: in some cell lineages the X with the normal allele is inactivated (mutant expressed), and in others the X with the mutant allele is inactivated (normal expressed). The result is a mosaic of normal and affected patches.

---

Role of Noncoding RNAs

Beyond mRNA: The RNA Regulatory World

Much of the transcriptome is noncoding RNA (ncRNA) — not translated, but regulating gene expression. The MCAT tests the major classes.

MicroRNA (miRNA) and Small Interfering RNA (siRNA)

Must know

MicroRNAs (miRNAs) are endogenous small RNAs that repress expression post-transcriptionally. A mature miRNA is loaded into a silencing complex and guides it to complementary sequences (usually the 3' UTR) of target mRNAs. Because the match is typically imperfect, the result is mainly blocked translation and mRNA destabilization. One miRNA can regulate many mRNAs.

Small interfering RNAs (siRNAs) use the same silencing complex but are usually perfectly complementary, triggering cleavage and degradation of the target. siRNAs are widely used experimentally to knock down a chosen gene.

These mechanisms are collectively RNA interference (RNAi).

miRNA vs. siRNA — the key distinction:

• miRNA: endogenous, imperfect complementarity, blocks translation + destabilizes mRNA, one miRNA → many targets.
• siRNA: often experimental, perfect complementarity, triggers mRNA cleavage, highly specific.

Long Noncoding RNAs (lncRNAs)

Passage-level

Long noncoding RNAs (lncRNAs) are longer noncoding transcripts that regulate gene expression in diverse ways, e.g., controlling chromatin state across a region (the RNA that coats and silences the inactive X). Know they exist as important regulators; mechanisms aren't required.

Quick check: A researcher introduces a double-stranded RNA perfectly complementary to a tumor-suppressor mRNA into cancer cells. What happens to expression of the tumor suppressor, and what mechanism is responsible?

The dsRNA enters the RNA interference (RNAi) pathway: it is processed into siRNA, loaded into the silencing complex, and the guide strand directs cleavage of the complementary tumor-suppressor mRNA. The mRNA is degraded and protein levels fall — a loss-of-function effect achieved post-transcriptionally.

---

Common Confusions & Tricks

1. Cis vs. trans — don't swap them. A cis element is a DNA sequence (promoter, enhancer, silencer, response element). A trans factor is a protein (transcription factor) that is encoded elsewhere and diffuses to its target. "Trans" = "transcription factor."

2. Dominant vs. recessive in cancer. Oncogenes are dominant (one mutant allele is enough — gain of function). Tumor suppressors are recessive (both alleles must be lost — loss of function, two-hit model). Students flip this constantly. Mnemonic: Oncogene = One hit is enough; Tumor suppressor = Two hits needed.

3. Acetylation always activates; histone methylation is context-dependent. For the MCAT, acetylation of histones = active chromatin. Histone methylation can activate or repress depending on the site, so don't overgeneralize it.

4. DNA methylation ≠ histone methylation. DNA methylation (on cytosine in CpG) = silencing. Histone methylation depends on the residue. Two very different things sharing the word "methylation."

5. miRNA vs. siRNA. If you see partial complementarity and blocked translation → miRNA. If you see perfect complementarity and mRNA cleavage → siRNA. Both work through an RNA-guided silencing complex; the distinction is the degree of match and the outcome.

6. Introns are removed; exons are expressed. If you see a mutation at a splice site, predict intron retention or exon skipping, not just a single amino acid change.

7. Gene amplification ≠ gene duplication. Duplication is an evolutionary mechanism that produces gene families (heritable). Amplification is a somatic increase in copy number to boost a gene's output — frequently seen in cancer cells.

---

Key Takeaways

Transcription Regulation

• Cis-regulatory elements: promoters (TATA box) and distant enhancers/silencers regulate transcription
• General (basal) transcription factors + RNA polymerase II assemble the initiation complex at the promoter
• Activators bind enhancers and recruit coactivators; enhancers act over distance via DNA looping; cis = DNA sequence, trans = protein factor
• Nuclear hormone receptors: lipid-soluble hormone binds receptor inside the cell → complex binds a response element → activates transcription (direct pathway)

DNA-Binding Protein Motifs

• Recognize by name: zinc finger, leucine zipper, helix-turn-helix
• TFs have modular DNA-binding and activation/repression domains

Gene Amplification and Duplication

• Gene families arise from evolutionary duplication (e.g., globin family)
• Gene amplification = somatic increase in copy number to raise a gene's output (e.g., in cancer)

Post-Transcriptional Control

• Pre-mRNA processing: 5' 7-methylguanosine cap, 3' poly-A tail, splicing
• Spliceosome (snRNPs) removes introns and joins exons; alternative splicing generates protein diversity from a single gene
• mRNA stability and translational control tune how much protein is made

Cancer Biology

• Oncogenes: gain-of-function, dominant (one hit); example: Ras
• Tumor suppressors: loss-of-function, recessive (multiple hits); examples: p53, Rb
• Cancer = accumulated mutations that defeat normal cell-cycle/expression controls

Chromatin Structure

• Nucleosome = histone octamer (2×H2A, H2B, H3, H4) wrapped by DNA; H1 linker histone
• Euchromatin (loose, active) vs. heterochromatin (compact, silent; constitutive or facultative, e.g. Barr body)
• Acetylation of histones = active chromatin (HATs add, HDACs remove); methylation can activate or repress depending on site
• Chromatin remodelers reposition nucleosomes to change DNA accessibility

DNA Methylation

• Methylation of cytosine at CpG islands in promoters → gene silencing; a heritable epigenetic mark
• Underlies genomic imprinting (parent-of-origin expression) and X-inactivation (Barr body; females are mosaics)

Noncoding RNAs

• miRNA: endogenous, imperfect complementarity (usually 3' UTR) → blocks translation + destabilizes mRNA; one miRNA → many targets
• siRNA: perfect complementarity → mRNA cleavage; used experimentally for knockdown (RNAi)
• lncRNA: longer noncoding regulators (e.g., the RNA that coats and silences the inactive X)